Topical Compositions Comprising An Alkoxylated Diphenylacrylate Compound And An Aryl Carboxylic Ester

A topical composition containing an alkoxylated diphenylacrylate compound and an aryl carboxylic ester is provided. Preferably, the topical composition is a sunscreen composition containing α-ethylhexyl α-cyano-β-(4-methoxyphenyl)-β-phenylacrylate and 2-phenylethyl benzoate, and optionally further containing 4,4′-t-butyl methoxydibenzoylmethane, which is characterized by improved photo-protection of the skin and is effective in preventing/reducing photo-damage of the skin upon exposure to sunlight or other sources of light in the ultraviolet (UV), visible, and infrared (IR) ranges.

Binary and tertiary galvanic particulates and methods of manufacturing and use thereof

The present invention relates to galvanic particulates, their methods of manufacture and uses in treatments are described. The galvanic particulates may be binary or tertiary galvanic particulates, for example, containing multiple layers or phases of conductive materials.

Rare earth nanoparticles

This document provides methods and materials related to rare earth particles such as rare earth nanorods (e.g., inorganic lanthanide hydroxide nanorods). For example, rare earth (e.g., lanthanide) particles such as europium hydroxide nanorods, methods and materials for making rare earth particles (e.g., europium hydroxide nanorods), and methods and materials for using rare earth particles (e.g., europium hydroxide nanorods) as an imaging agent and/or to promote angiogenesis are provided.

Inhibitors of brutons tyrosine kinase for the treatment of solid tumors

Described herein are irreversible Btk inhibitor compounds, and methods for using such irreversible inhibitors in the treatment of diseases and disorders characterized by the presence or development of solid tumors.

Rhenium complexes and their pharmaceutical use

The present invention is directed to a rhenium complex of general Formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein X is Se; Y is NH, O or S or is a methylene group; Z is halogen; m=0, 1, or 2 and p=0, 1, or 2, provided that m and p are both different from zero when Y is NH, O or S; n=3; R′ is a phenyl group or a group of general Formula —(CH 2 ) q —COOH wherein q=1 or 2, a pharmaceutical composition comprising a therapeutically effective amount of at least one of such rhenium complex where X is additionally S or Te, a method for preparing said rhenium complex and a method for treating a proliferative growth related-disorder using a therapeutically effective amount of at least one of said rhenium complex where X is additionally S or Te. Also claimed is the use of compounds of formula (II) in the preparation of compounds of formula (I).

Methods and compositions for malic enzyme 2 (me2) as a target for cancer therapy

The present invention relates to methods, compositions, and diagnostic tests for treating and diagnosing cancer and other related diseases that result in dysregulation of malic enzyme 2. In particular, the methods and compositions include combination therapy, such as with a combination of two or more ME2 inhibitors or a combination of an ME2 inhibitor and an anticancer agent.

Radiopaque Embolic Particles

A radiopaque particulate material one or more of SiO 2 , TiO 2 , La 2 O 3 , Na 2 O and MgO and useful for embolization which optionally includes therapeutic components that are released in vivo.

Administration of Growth Factors for the Treatment of CNS Disorders

A method and system that is directed to the local delivery of growth factors to the mammalian CNS to treat CNS disorders associated with neuronal death and/or dysfunction is described.

Orally administrable gallium compositions and methods of use

Provided are pharmaceutical gallium compositions that are particularly useful for oral administration. The pharmaceutical compositions include solid, liquid, and paste formulations, which have high oral gallium bioavailability and are suitable for human and veterinary applications. The compositions comprise pharmaceutically acceptable gallium compounds, such as gallium maltolate, gallium 8-quinolinolonate, or gallium nitrate, together with certain viscosity-increasing agents, such as water-soluble forms of methylcellulose or carboxymethylcellulose.

Nanoparticle- and Drug-Containing Polymersomes for Medical Applications

Provided are polymersomes for co-delivery of hydrophobic metallic nanoparticles and pharmaceutical agents and suspensions of such polymersomes. Also provided are methods of making such polymersomes and suspensions of polymersome and methods of using the same to treat diseases or conditions.

Uniform core-shell tio2 coated upconversion nanoparticles and use thereof

An upconversion nanoparticle (UCN) coated with a layer of semiconductor material is disclosed. The UCN core acts as a nanotransducer to convert near infrared (NIR) to visible and/or ultraviolet (UV) light while the semiconductor shell serves as a photocatalyst. Upon excitation by NIR light, the UCN upconverts NIR light to UV and/or visible light of different wavelengths. Spectral overlap between the emitted UV and absorption wavelength of the coated TiO 2 activates the TiO 2 layer to generate cytotoxic reactive oxygen species (ROS), which can be used in photodynamic therapy for the treatment of cancer cells. Stability and uptake of the nanoparticles can be increased by altering the coating of the nanoparticle, such as by a polymer and a dispersion stabilizer.

Rare earth metal compounds, methods of making, and methods of using the same

Rare earth metal compounds, particularly lanthanum, cerium, and yttrium, are formed as porous particles and are effective in binding metals, metal ions, and phosphate. A method of making the particles and a method of using the particles is disclosed. The particles may be used in the gastrointestinal tract or the bloodstream to remove phosphate or to treat hyperphosphatemia in mammals. The particles may also be used to remove metals from fluids such as water.

METHODS OF USE OF ULTRA-HIGH DOSE RATE RADIATION AND THERAPEUTIC AGENT

Methods for treating tumors by administering FLASH radiation and a therapeutic agent to a patient with cancer are disclosed. The methods provide the dual benefits of anti-tumor efficacy plus normal tissue protection when combining therapeutic agents with FLASH radiation to treat cancer patients. The methods described herein also allow for the classification of patients into groups for receiving optimized radiation treatment in combination with a therapeutic agent based on patient-specific biomarker signatures. Also provided are radiation treatment planning methods and systems incorporating FLASH radiation and therapeutic agents. 1. A method for treating a tumor in a subject with cancer , the method comprising administering an effective amount of ultra-high-dose-rate (FLASH) radiation and a therapeutic agent to the tumor.2. The method of claim 1 , wherein the method reduces damage to normal tissue when compared to administering conventional radiation at a dose of 0.5 Gy/sec to the tumor.3. The method of claim 1 , wherein the radiation is administered at a dose rate equal to or greater than 40 Gy/sec claim 1 , or the dose is administered in 1 second or less claim 1 , and the radiation is administered in a single pulse or in multiple pulses.4. The method of claim 1 , wherein the radiation comprises or consists of protons.5. The method of claim 1 , wherein the therapeutic agent is an immune modulator claim 1 , a senolytic agent claim 1 , a radiosentizer claim 1 , or a nanoparticle.6. The method of claim 1 , wherein the therapeutic agent is a mitotic spindle inhibitor claim 1 , a DNA damage repair and response inhibitor claim 1 , a MAPK pathway inhibitor claim 1 , an epithelial to mesenchymal (EMT) inhibitor claim 1 , an activator of T helper type 1 (TH1) lymphocytes claim 1 , an activator of the PTEN pathway claim 1 , and inhibitor of the TGF-beta pathway claim 1 , an activator of the type-1 interferon signaling pathway claim 1 , an activator of dendritic cell ...

WATER-SOLUBLE NANOCERIA AND METHODS OF MAKING AND USING THE SAME

Water-soluble nanoceria are described herein along with methods of making and using the same. Water-soluble nanoceria described herein comprise a cerium oxide nanoparticle and glycol chitosan. In some embodiments, water-soluble nanoceria further comprise at least one therapeutic agent and/or targeting agent that may be attached to a surface of the water-soluble nanoceria. 1. A water-soluble nanoceria comprising a cerium oxide nanoparticle and glycol chitosan.2. The water-soluble nanoceria of claim 1 , wherein the cerium oxide nanoparticle is prepared from a cerium salt.3. (canceled)4. The water-soluble nanoceria of claim 1 , wherein the cerium oxide nanoparticle is present in an amount of about 10% to about 30% by weight of the water-soluble nanoccria and the glycol chitosan is present in an amount of about 60% to about 80% by weight of the water-soluble nanoceria.5. The water-soluble nanoceria of claim 1 , wherein the glycol chitosan coats at least a portion of an exterior surface of the cerium oxide nanoparticle.6. The water-soluble nanoceria of claim 1 , wherein at least one therapeutic agent and/or targeting agent is attached to a surface of the water-soluble nanoceria.7. The water-soluble nanoceria of claim 1 , wherein the cerium oxide nanoparticle has a diameter in a range of about 2 nm to about 6 nm.8. The water-soluble nanoceria of claim 1 , wherein the cerium oxide nanoparticle has a crystalline structure.9. The water-soluble nanoceria of claim 1 , wherein the cerium oxide nanoparticle is monodisperse.10. (canceled)11. The water-soluble nanoceria of claim 1 , wherein the cerium oxide nanoparticle has a cubic fluorite structure.12. The water-soluble nanoceria of claim 1 , wherein the water-soluble nanoceria have a hydrodynamic diameter in a range of about 100 nm to about 200 nm.13. The water-soluble nanoceria of claim 1 , wherein the water-soluble nanoceria have a zeta potential in a range of about +10 to about +40.14. The water-soluble nanoceria of claim 1 ...

Capsule and powder formulations containing lanthanum compounds

The present invention includes an oral pharmaceutical capsule comprising a shell, lanthanum carbonate or lanthanum carbonate hydrate, and a lubricant such as talc, wherein the shell encapsulates the lanthanum carbonate or its hydrate and the lubricant. Capsule shells comprise, for example, gelatin. The present invention also includes an oral pharmaceutical powder comprising lanthanum carbonate or lanthanum carbonate hydrate and a pharmaceutically acceptable excipient. The oral pharmaceutical capsules and powders of the present invention can be administered to treat a patient at risk of or suffering from hyperphosphatemia, at risk of or suffering from chronic kidney disease (CKD), at risk of or suffering from soft tissue calcification associated with CKD, or at risk of or suffering from secondary hyperparathyroidism.

Silicon nanoparticle with platinum anti-cancer agent

Disclosed herein, inter alia, are compositions and methods of using the same for treating cancer.

Methods of use of ultra-high dose rate radiation and therapeutic agent

Methods for treating tumors by administering FLASH radiation and a therapeutic agent to a patient with cancer are disclosed. The methods provide the dual benefits of anti-tumor efficacy plus normal tissue protection when combining therapeutic agents with FLASH radiation to treat cancer patients. The methods described herein also allow for the classification of patients into groups for receiving optimized radiation treatment in combination with a therapeutic agent based on patient-specific biomarker signatures. Also provided are radiation treatment planning methods and systems incorporating FLASH radiation and therapeutic agents.

TOPICAL SILK COMPOSITIONS AND METHODS OF USING

Methods of protecting skin of a mammal by application of silk-derived compositions useful for treating or preventing a wide variety of skin conditions. Silk solutions and silk mats are prepared and applied to the skin surface. The silk compositions may be self-adhesive or sutured to cover a wound or area of skin exposed to physical stresses and strains, thereby preventing a wound and/or promoting wound healing. 1. A method of protecting skin of a mammal comprising:applying a solution of silk fibroin fibers to the skin of a mammal; andapplying a silk fibroin mat over the solution of silk fibroin fibers applied to the skin of the mammal;thereby increasing the elastic modulus of the skin of the mammal2. The method of claim 1 , wherein the silk fibroin fibers in the solution have a diameter in a range of about 1 to about 1 claim 1 ,000 nm.3. The method of claim 1 , wherein the silk fibroin fibers in the solution are obtained from another solution containing a dissolved silkworm silk or a dissolved spider silk.4. (canceled)5. (canceled)6. (canceled)7. The method of claim 1 , wherein the silk fibroin fibers in the solution have a sericin content of less than 5%.8. (canceled)9. The method of claim 1 , wherein the silk fibroin fibers in the solution have a concentration of about 0.1 to about 25 weight percent of the solution.10. The method of claim 1 , wherein the solution of silk fibroin fibers is an aqueous solution or an alcohol solution.11. (canceled)12. The method of claim 1 , wherein the solution of silk fibroin fibers further comprises a biocompatible polymer selected from the group comprising polyethylene oxide (PEO) claim 1 , polyethylene glycol (PEG) claim 1 , collagen claim 1 , fibronectin claim 1 , keratin claim 1 , polyaspartic acid claim 1 , polylysine claim 1 , alginate claim 1 , chitosan claim 1 , chitin claim 1 , hyaluronic acid claim 1 , pectin claim 1 , polycaprolactone claim 1 , polylactic acid claim 1 , polyglycolic acid claim 1 , polyhydroxyalkanoates ...

Composition for prophylaxis and treatment of bone disorders

A composition for use in medicine or as a dietary supplement, the composition including at least one complex or salt of trivalent metal cation (Me 3+ ) with inorganic polyphosphate (polyP), wherein the trivalent metal cation (Me 3+ ) is selected from the elements of the group consisting of Al, In, La, Ce, Pr, Nd, Sm, Eu, Gd, Tb, Dy, Ho, Er, Tm, Yb and Lu.

METHODS FOR RADIOTHERAPY TO TRIGGER LIGHT ACTIVATION DRUGS

A method and system for treating a subject with a disorder which provides within the subject at least one photoactivatable drug for treatment of the subject, applies initiation energy from at least one source to generate inside the subject a preferential x-ray flux for generation of Cherenkov radiation (CR) light capable of activating at least one photoactivatable drug, and from the CR light, activating inside the subject the at least one photoactivatable drug to thereby treat the disorder.

NOVEL COMPOUND, ANTIINFLAMMATORY DRUG COMPRISING THE COMPOUND AND CYCLOOXYGENASE-2 INHIBITOR COMPRISING THE COMPOUND

A compound is disclosed that can be used as an anti-inflammatory agent, a cyclooxygenase-2 inhibitor, a therapeutic agent for brain diseases, or a MRI contrast medium. The compound can have the structure represented by chemical formula 1. 5. The compound of claim 1 , wherein the compound targets an inflammation site and diagnoses the inflammation site in a targeting manner claim 1 , and has anti-inflammatory activity on the inflammation site.6. The compound of claim 1 , wherein the compound has anti-inflammatory activity by selectively inhibiting cyclooxygenase-2 (COX-2) at an inflammation site.7. The compound of claim 3 , wherein the compound is used for targeting diagnosis of a brain inflammation site claim 3 , and has anti-inflammatory activity on the brain inflammation site.8. The compound of claim 1 , wherein the compound has relaxivity of 4 mMsto 5 mMson a 1.5 T magnetic resonance image (MRI).9. The compound of claim 1 , wherein the compound coordinates with at least one water molecule.14. The method of claim 10 , wherein the anti-inflammatory agent selectively inhibits cyclooxygenase-2 (COX-2) at an inflammation site.15. The method of claim 12 , wherein the compound targets a brain inflammation site claim 12 , and has anti-inflammatory activity on the brain inflammation site.20. The method of claim 18 , wherein the MRI contrast agent specifically targets a cerebral infarction site to strongly increase a signal related to the cerebral infarction site.2129-. (canceled)30. The method of claim 12 , wherein the method treats the brain inflammatory disease.31. The method of claim 30 , wherein the brain inflammatory disease includes dementia and cerebral stroke.32. The compound of claim 4 , wherein the compound is used for targeting diagnosis of a brain inflammation site claim 4 , and has anti-inflammatory activity on the brain inflammation site.33. The method of claim 13 , wherein the compound targets a brain inflammation site claim 13 , and has anti-inflammatory ...

REMOVAL OF EUROPIUM IMPURITIES FROM SAMARIUM-153 IN NITRATE MEDIA USING IONIC LIQUIDS

A process of isolating samarium from a hydrophilic composition comprises nitrate ions, europium and samarium, by reducing europium(III) to europium(II) in this hydrophilic composition, and by extracting the samarium with a water-immiscible organic phase comprising an ionic liquid comprising nitrate anions. 123.-. (canceled)24. A process of isolating samarium from a hydrophilic composition comprising nitrate ions , europium and samarium , the process comprising the steps of:a) reducing europium(III) to europium(II) in said hydrophilic composition; andb) extracting said samarium with a water-immiscible organic phase comprising an ionic liquid comprising nitrate anions.25. The process according to claim 24 , wherein said samarium is samarium-153.26. The process according to claim 24 , wherein the hydrophilic composition in step a) does not contain chloride ions.27. The process according to claim 24 , wherein the anions in the hydrophilic composition in step a) and in the water-immiscible organic phase in step b) consist of nitrate anions.28. The process according to claim 24 , further comprising the step of:c) back-extracting samarium to a hydrophilic composition wherein said concentration of nitrate ions is lower than the concentration of nitrate ions in the hydrophilic composition of step a).29. The process according to claim 24 , wherein the ionic liquid is tricaprylmethylammonium nitrate or benzyl¬trioctyl¬ammonium nitrate.30. The process according to claim 24 , wherein the hydrophilic composition is an aqueous solution.31. The process according to claim 24 , wherein the ionic liquid is impregnated on a solid support.32. The process according to claim 31 , wherein the solid support is a porous organic polymer.33. The process according to claim 32 , wherein the porous organic polymer is a polystyrene-polydivinylbenzene copolymer claim 32 , or a insoluble aliphatic polyacrylic ester.34. The process according to claim 31 , wherein the solid support is a porous ...

Chelated Metal Oxide Gel Compositions

Described is a homogeneous gel composition with at least antimicrobial, antibacterial, and/or anti-viral properties comprising; a combination of a stable and homogeneous aqueous and/or polyol solution based chelated metal oxide liquid complex suspension and a gel composition free of chelated metal oxides comprising water, polyquaternium, glycerine and hyaluronic acid, wherein the homogeneous gel composition contains chelated metal oxide particles homogeneously suspended in the homogeneous gel composition such that a concentration of the chelated metal oxide particles contained within the homogeneous gel are in a concentration of at least 0.001 weight percent.

Nanoparticle compositions and methods for treating or preventing tissue infections and diseases

Stabilized multi-component antimicrobial compositions for treating tissue diseases, infections or conditions include a first and second set of differently sized and/or differently shaped metal nanoparticles, and a stabilizing agent. Compositions and treatment methods may be used for treating tissue diseases, infections or conditions caused by microbial infections, such as bacteria, viral, and/or fungal infections, or for preventing the infection of a wound, such as a cut, abrasion, ulcer, lesion, sore, and the like. The compositions and treatment methods disclosed herein may also be used as a prophylactic, and in some embodiments may be applied to otherwise healthy tissue in order to prevent or reduce the occurrence of a tissue disease, infection or condition.

Novel use

The present invention relates to a combination comprising at least one compound selected from the group consisting of an α-adrenergic antagonist, an anthelmintic agent, an antifungal agent, an antimalarial agent, an antineoplastic agent, an antipsychotic agent, an antioxidant, a vasodilator, a vitamin, or a pharmaceutically acceptable derivative thereof; and an antimicrobial compound.

EDDS CHELATED NANOCERIA WITH CATALASE-LIKE ACTIVITY

A process for making nanoparticles of biocompatible materials is described, wherein an aqueous reaction mixture comprising cerous ion, ethylenediaminedisuccinic acid, an oxidant, water, and optionally citric acid, is provided along with temperature conditions to directly form within the reaction mixture, a stable dispersion of cerium oxide nanoparticles. Biocompatible nanoparticles comprised of cerium oxide, ethylenediaminedisuccinic acid, and optionally citric acid, are described. An increase in catalase-like enzyme activity is demonstrated by cerium oxide nanoparticles prepared with citric acid and ethylenediaminedisuccinic acid. 115.-. (canceled)16. A nanoparticle comprising cerium oxide , citric acid and ethylenediaminedisuccinic acid.17. The nanoparticle of claim 16 , wherein said nanoparticles have a hydrodynamic diameter less than about 30 nanometers.18. The nanoparticle of claim 16 , wherein said nanoparticles have a hydrodynamic diameter less than about 5 nanometers.19. A dispersion comprising cerium oxide nanoparticles claim 16 , citric acid claim 16 , ethylenediaminedisuccinic acid and water.20. The dispersion of claim 19 , wherein said nanoparticles have a hydrodynamic diameter less than about 30 nanometers.21. The dispersion of claim 19 , wherein said nanoparticles have a hydrodynamic diameter less than about 5 nanometers.22. The dispersion of claim 19 , wherein said nanoparticles are substantially non-agglomerated.23. The dispersion of claim 19 , wherein the pH ranges from about 6.5 to about 8.0.24. The dispersion of claim 23 , wherein the pH ranges from about 7.0 to about 7.4. This application is a continuation application of U.S. Ser. No. 16/886,033, filed May 28, 2020, which is a divisional application of U.S. Ser. No. 15/545,065, filed Jul. 20, 2017, now U.S. Pat. No. 10,722,474, which is a U.S. national stage application of PCT International Application No. PCT/US2016/014076, filed Jan. 20, 2016, which is a PCT international application claiming ...

Cosmetic Compositions With Near Infra-Red (NIR) Light - Emitting Material And Methods Therefor

Cosmetic or dermatological compositions and substrates, containing a NIR light-emitting material, and methods for stimulating healing and/or regenerative properties in the skin, hair and/or scalp are provided.

Nanoparticles of Cerium Oxide Targeted to an Amyloid Beta Antigen of Alzheimer's Disease and Associated Methods

Disclosed is a composition immunologically targeted to Alzheimer's disease (AD), the composition containing amine functionalized nanoparticles of Cerium oxide coated with polyethylene glycol and bearing an antibody specific for an amyloid-beta antigen associated with AD. The invention also includes a medication manufactured with the targeted nanoceria particles and methods of treatment by administering the targeted nanoceria particles to patients in need thereof.

Mineral water composition

A mineral water comprising a composition of a blend of minerals and trace rare earth elements is provided, the rare earth elements in the composition comprise Scandium, Yttrium, Lanthanum, Cerium, Praseodymium, Neodymium, Samarium, Europium, Gadolinium, Terbium, Dysprosium, Holmium, Erbium, Thulium, Ytterbium, Lutetium. The water is conducive to good health and can relieve the symptoms of some chronic diseases.

Surface-Modified Heavy Metal Nanoparticles, Compositions And Uses Thereof

Surface-modified heavy metal nanoparticles, including a heavy metal core and a coating layer, the coating layer having at least one ligand, conjugated to polyethylene glycol, the at least one ligand is selected from N-acetyl cysteine, albumin, cysteine, methionine, glutathione, amino thiols, thio-carboxylic acids, ammonia, amines, diamines or any combination thereof. Compositions including surface-modified heavy metal nanoparticles and uses thereof in treatment and diagnosis of various conditions.

LASER ENHANCER COMPOSITION FOR IMPROVING MELASMA, WRINKLES, SKIN TIGHTENING, PORES, AND ACNE

Proposed is a laser enhancer composition for improving melasma, wrinkles, skin tightening, pores, and acne by removing dead skin cells on an epidermal layer of the skin. The laser enhancer composition is used in a form applied to the epidermal layer during the treatment. The laser enhancer composition includes: either one or both of a peeling material and a heat conducting material that are configured not to be vaporized by a laser so that fumes are not generated; a viscous material configured to mix the peeling material and the heat conducting material due to viscosity thereof; a volatile alcohol; and purified distilled water. 1. A laser enhancer composition for removing dead skin cells on an epidermal layer during a laser peeling treatment , thereby improving melasma , wrinkles , skin tightening , pores , and acne , the laser enhancer composition being used in a form applied to the epidermal layer during the treatment , the laser enhancer composition comprising:either one or both of a peeling material and a heat conducting material that are configured not to be vaporized by a laser so that fumes are not generated;a viscous material configured to mix the peeling material and the heat conducting material due to viscosity thereof;a volatile alcohol; andpurified distilled water.2. The laser enhancer composition of claim 1 , wherein the peeling material comprises diamond in a powder form with a predetermined particle size so as to enable skin peeling claim 1 , andthe heat conducting material comprises any one of a magnetic substance, gold, and platinum that are in a powder form with a predetermined particle size or comprises a mixture thereof so as to enable heat conduction.3. The laser enhancer composition of claim 2 , wherein each of the peeling material and the heat conducting material has a particle size of 1 to 5 μm to maximize a peeling effect and to obtain an appropriate amount of absorption.4. The laser enhancer composition of claim 2 , wherein the magnetic ...

Compositions including triciribine and methods of use thereof

This invention encompasses combination therapies including TCN, TCN-P, TCN-PM and/or related compounds and one or more additional anti-cancer agents, for example, taxanes a molecule that modulates the HER2/neu (erbB2) receptor, anthracyclin compounds, epidermal growth factor receptor inhibitor compounds, one or more platinum compounds and bortezomib and derivatives thereof and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation.

Environmentally Sensitive Compositions and Methods of Use Thereof

An environmentally sensitive membrane binding polypeptide, pH (low)-sensitive membrane peptide (pHLIP) has improved insertion kinetics balanced with solubility to selectively target acidic tissues.

Composition for anticancer adjuvant comprising rip3 expression promoter as active ingredient, method for screening anticancer adjuvant which promotes rip3 expression and enhances sensitivity of anticancer agent, and method for monitoring sensitivity of anticancer agent

The present invention relates to a pharmaceutical composition for an anticancer adjuvant comprising a receptor-interacting protein kinase-3 (RIP3) protein expression promotor or activator as an active ingredient. In addition, the present invention provides a method of promoting cancer cell apoptosis, characterized by co-administering an anticancer agent and a RIP3 protein expression promotor or activator to cancer cells. Also, the present invention relates to a method for screening an anticancer adjuvant which promotes RIP3 expression and enhances sensitivity of an anticancer agent, and a method for monitoring sensitivity of an anti-cancer agent depending on the RIP3 expression. Accordingly, in the case of a patient lacking the expression of RIP3, it is expected to be an effective treatment strategy to pre-treat a demethylating agent to induce the expression of RIP3 and then to use a conventional chemotherapeutic agent. In addition, in chemotherapy, it is anticipated that the present invention may be an effective strategy in screening an anticancer adjuvant which monitors and enhances sensitivity of an anticancer agent.

METHOD FOR PREPARING STABILIZED METAL ION LIGAND NANOCOMPLEX AND COMPOSITIONS THEREOF

The present disclosure provides method of making a nanoparticle complex wherein the nanoparticle complex comprises a ligand and a metal cation. The disclosure also provides nanoparticle complexes, methods of treating a disease in a patient utilizing the nanoparticle complexes, methods of identifying a disease in a patient utilizing the nanoparticle complexes, and kits involving the nanoparticle complexes. 1. A method of making a nanoparticle complex , said method comprising the steps of:providing a first composition, wherein the first composition comprises at least one ligand;{'sub': n', 'y, 'providing a second composition, wherein the second composition comprises a salt of the formula MX,'}wherein M is a metal cation and X is counterion, andwherein n is an integer from 1 to 3 and y is an integer from 1 to 5; andcombining the first composition and the second composition to obtain the nanoparticle complex, wherein the nanoparticle complex comprises the ligand and M.2. The method of claim 1 , wherein the ligand is an organic molecule is capable of forming a complex with the metal cation claim 1 , wherein the organic molecule comprises an atom or a functional group capable of donating an electron pair to the metal cation claim 1 , and wherein the atom or the functional group is selected from the group consisting of S-donor claim 1 , O-donor claim 1 , N claim 1 ,O-donor claim 1 , N-donor claim 1 , P-donor claim 1 , Lewis base claim 1 , Shiff base claim 1 , macrocycle claim 1 , and N—N dimine donor.3. The method of claim 1 , wherein the ligand is a therapeutic agent claim 1 , and wherein the therapeutic agent is diethyldithiocarbamatetrihydrate (DDC).4. The method of claim 1 , wherein the ligand is a therapeutic agent and wherein the therapeutic agent is selected from the group consisting of paclitaxel claim 1 , docetaxel claim 1 , and doxorubicin.5. The method of claim 1 , wherein the ligand is an imaging agent.6. The method of claim 1 , wherein M is selected from the ...

METHODS FOR PREVENTING AND TREATING PULMONARY INFLAMMATION AND FIBROSIS

Methods of treating, reducing the risk of, preventing, or alleviating a symptom of a pulmonary disease or condition, reducing or suppressing inflammation in the lung, and promoting lung repair, by pulmonary administration of a cerium oxide nanoparticle composition. 1. A method of treating , reducing the risk of , preventing , or alleviating a pulmonary disease or condition in a subject , comprising administering to the subject a therapeutically effective amount of a cerium oxide nanoparticle (CNP).2. The method of claim 1 , wherein the CNP comprises a therapeutic agent.3. The method of or claim 1 , wherein the therapeutic agent is an anti-inflammatory agent.4. The method of or claim 1 , wherein the therapeutic agent is a micro-RNA (miRNA).5. The method of any one of - claim 1 , wherein the miRNA is miRNA-146a.6. The method of or claim 1 , wherein the miRNA is covalently attached to the CNP.7. The method of or claim 1 , wherein the miRNA is non-covalently associated with the CNP.8. The method of any one of - claim 1 , wherein the pulmonary disease or condition is selected from pulmonary inflammation claim 1 , pulmonary fibrosis claim 1 , obstructive pulmonary disease (COPD) claim 1 , emphysema claim 1 , asthma claim 1 , idiopathic pulmonary fibrosis claim 1 , pneumonia claim 1 , tuberculosis claim 1 , cystic fibrosis claim 1 , bronchitis claim 1 , pulmonary hypertension (e.g. claim 1 , Idiopathic Pulmonary Arterial Hypertension (IPAH) claim 1 , interstitial lung disease claim 1 , and lung cancer.9. The method of claim 8 , wherein the pulmonary disease or condition is selected from pulmonary inflammation claim 8 , pulmonary fibrosis claim 8 , COPD claim 8 , emphysema claim 8 , asthma claim 8 , pulmonary fibrosis claim 8 , and cystic fibrosis.10. The method of any one of - claim 8 , wherein the pulmonary disease or condition is caused by inflammation claim 8 , autoimmune disease claim 8 , scleroderma claim 8 , rheumatoid arthritis claim 8 , Acute Lung Injury (ALI) ...

HYDROLYZED TETRAVALENT METAL SALTS AND METHODS OF BIOFILM INHIBITION

Described herein are hydrolyzed tetravalent salts and formulations thereof that can be used to inhibit a biofilm. Also described herein are uses of the hydrolyzed tetravalent salts and formulations thereof to inhibit a biofilm and/or treat biofilm infection. 1. A pharmaceutical formulation effective to inhibit a biofilm comprising:a therapeutically effective amount of a hydrolyzed tetravalent metal salt; anda pharmaceutically acceptable carrier.2. The pharmaceutical formulation of claim 1 , wherein the hydrolyzed tetravalent metal salt is a hydrolysis product of a Ce(IV) salt claim 1 , a Zr(IV) salt claim 1 , or a Ti(IV) salt.3. The pharmaceutical formulation of claim 1 , wherein the hydrolyzed tetravalent metal salt is present as a mononuclear complex claim 1 , an oligomer claim 1 , a polymer claim 1 , or a nanoparticle.4. The pharmaceutical formulation of claim 1 , wherein the hydrolyzed tetravalent metal salt is a hydrolysis product of Ce(IV) salt.5. The pharmaceutical formulation of claim 1 , wherein the hydrolyzed tetravalent metal salt is CeO.6. The pharmaceutical formulation of claim 5 , wherein the CeOis formulated as nanoparticles.7. The pharmaceutical formulation of claim 6 , wherein the nanoparticles have an average hydrodynamic radius of about 2-10 nm or less.8. The pharmaceutical formulation of claim 1 , further comprising an additional metal salt selected from the group consisting of: salts of Ca(II) claim 1 , Sr(II) claim 1 , Ba(II) claim 1 , Zn(II) claim 1 , Cu (II) claim 1 , Be(II) claim 1 , Ni(II) claim 1 , Fe(II) claim 1 , Co(II) claim 1 , Mn(II) claim 1 , Cr(II) claim 1 , V(II) claim 1 , Ti(II) claim 1 , Sc(II) claim 1 , Cd(II) claim 1 , Hg(II) claim 1 , cacodylic acid (As) sodium salt claim 1 , and any combination thereof.9. A method of inhibiting a biofilm in a subject in need thereof claim 1 , the method comprising: a therapeutically effective amount of a hydrolyzed tetravalent metal salt; and', 'a pharmaceutically acceptable carrier., ' ...

PARTICLES FOR THE TREATMENT OF CANCER IN COMBINATION WITH RADIOTHERAPY

The invention provides a particle comprising a first semiconductor and a second semiconductor wherein the first semiconductor forms a heterojunction with the second semiconductor. The invention also provides a pharmaceutical composition comprising the particles, and relates to uses of the particles and composition in the treatment of cancer in combination with radiotherapy. 1. A particle comprising a first semiconductor and a second semiconductor wherein the first semiconductor forms a heterojunction with the second semiconductor.2100-. (canceled) The invention relates to a particle and a pharmaceutical composition comprising a plurality of particles. The invention further relates to the use of the particle or pharmaceutical composition in the treatment of cancer in combination with radiotherapy.Cancer is a class of diseases characterised by uncontrolled cell division. There are over 200 types of cancer which can develop within the body. As there are different types of cells within each organ there are multiple types of cancer that can develop at any given site. Cancer harms the body when damaged cells divide uncontrollably and form solid lumps called tumours which interfere with body functions and hormone levels as they grow. Tumours become much more difficult to treat once they undergo metastasis; the process when a cancer cell moves throughout the body using the blood or lymph systems, invades healthy tissue and begins to divide and grow to form a new tumour. One critical aspect of tumour structure is the presence of oxygen deficient, or hypoxic, regions which form as a result of blood vessel growth being slower than cellular division. These dormant regions are indicative of poor prognosis as they contain cells that are most resistant to either natural or treatment-induced cell death.Radiotherapy is a key treatment for cancer, being used in approximately 50% of cancer treatments in the developed world. Radiotherapy can be used to cure cancer. It is estimated that ...

Administration of growth factors for the treatment of cns disorders

A method and system that is directed to the local delivery of growth factors to the mammalian CNS to treat CNS disorders associated with neuronal death and/or dysfunction is described.

Bladder Cancer Photodynamic Therapeutic Agents with Off-On Magnetic Resonance Imaging Enhancement

Provided herein are porphyrinato-lanthanide complexes useful as theranostic agents and methods of preparation and use thereof. The porphyrinato-lanthanide complexes are useful in the treatment and imaging of cancer.

Compositions and methods relating to molecular cerium-oxide nanoclusters

Described herein are compositions and methods relating to molecular cerium-oxide nanoclusters. In an aspect, described herein are methods of synthesizing molecular cerium-oxide nanocluster compositions and compositions thereof. In an aspect, described herein are methods of scavenging reactive oxygen species utilizing molecular cerium-oxide nanoclusters as described herein. Also described herein are pharmaceutical compositions and methods of use. Pharmaceutical compositions as described herein can comprise a therapeutically effective amount of a compound (such as a composition comprising one or more molecular cerium-oxide nanoclusters), or a pharmaceutically acceptable salt of the compound, and a pharmaceutically acceptable carrier. Methods of treating oxidative stress are also described herein, comprising administering pharmaceutical compositions as described herein to a subject in need thereof. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

Constructs, Agents, and Methods for Facilitated Ablation of Cardiac Tissue

The presently disclosed subject matter provides agents, compositions, and methods for augmenting ablation of a target tissue in a subject in need thereof, for example, using agents that modulate protective and/or reparative cellular processes induced in target tissue by application of ablative energy to the target tissue to sensitize the target tissue to the ablative energy. The presently disclosed subject matter further provides methods for augmenting radiofrequency ablation of cardiac tissue, for example, by applying radiofrequency energy to ablate cardiac tissue in the presence of metallic nanoparticles magnetically guided to the cardiac tissue.

Microporous zirconium silicate for the treatment of hyperkalemia

The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia.

Lanthanum carbonate compositions

The invention relates to stable oral pharmaceutical compositions comprising lanthanum carbonate compounds and pharmaceutically acceptable excipients. The compositions of the present invention are formulated without the use of flow aids or lubricants. The compositions of the present invention have physical properties & flowability indicators comparable to that of the powders containing flow aids or lubricants and these compositions can be filled in sachets without any difficulty.

METHOD AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OF NEURODEGENERATION

The present invention provides pharmaceutical compositions comprising a metal-desferrioxamine B complex or a combination thereof, for preventing, inhibiting, reducing or ameliorating neurodegeneration, thereby treating diseases, disorders, or conditions characterized by or associated with neurodegeneration; as well as methods of use. 1. A method for preventing , inhibiting , reducing or ameliorating neurodegeneration in a subject in need thereof , comprising administering to said subject a therapeutically effective amount of at least one metal-desferrioxamine B complex (metal-DFO complex).2. The method of claim 1 , wherein said metal-DFO complex each independently is the zinc- claim 1 , gallium- claim 1 , indium- claim 1 , silver- claim 1 , cobalt- claim 1 , or gold-DFO complex claim 1 , or a lanthanide-DFO complex.3. The method of claim 2 , comprising administering Zn-DFO complex claim 2 , Ga-DFO complex claim 2 , Eu-DFO complex claim 2 , Gd-DFO complex claim 2 , or a combination thereof.4. The method of claim 3 , comprising administering a combination of Zn-DFO complex and Ga-DFO complex claim 3 , wherein the quantitative ratio of said Zn-DFO complex to said Ga-DFO complex in said combination is in a range of 100:1 to 1:100.5. The method of claim 3 , comprising administering a combination of Zn-DFO complex claim 3 , Ga-DFO complex claim 3 , and at least one additional metal-DFO complex.6. The method of claim 1 , wherein said subject suffers from a neurodegenerative disease claim 1 , disorder or condition.7. The method of claim 1 , wherein said subject suffers from a disorder or condition induced by an injury.8. The method of claim 1 , wherein said subject suffers from a disease claim 1 , disorder or condition caused by prion.918-. (canceled)19. A kit comprising:(i) a first pharmaceutical composition comprising desferrioxamine B (DFO) or a pharmaceutically acceptable salt thereof;(ii) a second pharmaceutical composition comprising ions of at least one metal; and( ...

Antimicrobial compositions and methods

Antimicrobial compositions for killing or deactivating microbes, such as viruses, bacteria, or fungi, include metal nanoparticles, a carrier, and a plurality of metal nanoparticles. The nanoparticles can be selected to have a particle size and particle size distribution to selectively and preferentially kill one of a virus, a bacterium, or a fungus. Antiviral compositions can include nanoparticles having a particle size of 8 nm or less, 1-7 nm, 2-6.5 nm, or 3-6 nm (or up to 10 nm for Ebola virus). Antibacterial compositions can include nanoparticles having a particle size of 3-14 nm, 5-13 nm, 7-12 nm, or 8-10 nm. Antifungal compositions can include nanoparticles having a particle size of 9-20 nm, 10-18 nm, 11-16 nm, or 12-15 nm. Exemplary methods of killing or deactivating microbes include: (1) applying an antimicrobial composition to a substrate containing microbes, and (2) the antimicrobial composition killing or deactivating the microbes.

BIOCOMPATIBLE PHOTOTHERMAL COMPOSITION FOR TREATMENT OF CANCER AND SKIN DISEASES

The present invention relates to a biocompatible photothermal composition that can be used in various fields including the treatment of cancer and skin diseases. 2. (canceled)3. The photothermal composition according to claim 1 , wherein the metal salt is a lanthanide metal salt or a transition metal salt.4. The photothermal composition according to claim 3 , wherein the lanthanide metal salt is one or more metals selected from the group consisting of cerium (Ce) claim 3 , europium (Eu) claim 3 , gadolinium (Gd) and terbium (Tb).5. The photothermal composition according to claim 3 , wherein the transition metal salt is one or more metals selected from the group consisting of aluminum (Al) claim 3 , vanadium (V) claim 3 , manganese (Mn) claim 3 , iron (Fe) claim 3 , zinc (Zn) claim 3 , zirconium (Zr) claim 3 , molybdenum (Mo) claim 3 , ruthenium (Ru) and rhodium (Rh).6. (canceled)7. (canceled)8. (canceled)9. The photothermal composition according to claim 1 , wherein the photothermal composition is characteristically used for the treatment of cancer.10. The photothermal composition according to claim 9 , wherein the cancer is a solid cancer or a blood cancer.11. The photothermal composition according to claim 10 , wherein the solid cancer is brain tumor claim 10 , benign astrocytoma claim 10 , malignant astrocytoma claim 10 , pituitary adenoma claim 10 , meningioma claim 10 , brain lymphoma claim 10 , oligodendroglioma claim 10 , intracranial carcinoma claim 10 , ependymoma claim 10 , brain stem tumor claim 10 , head and neck cancer claim 10 , laryngeal cancer claim 10 , oropharyngeal cancer claim 10 , nasal cavity cancer claim 10 , nasopharyngeal cancer claim 10 , salivary gland cancer claim 10 , hypopharyngeal cancer claim 10 , thyroid cancer claim 10 , oral cancer claim 10 , thoracic tumor claim 10 , small cell lung cancer claim 10 , non-small cell lung cancer claim 10 , thymic carcinoma claim 10 , mediastinal tumor claim 10 , esophageal cancer claim 10 , breast ...

Therapeutic combinations comprising poly (ADP-ribose) polymerases inhibitor

This invention generally relates to use of 8-fluoro-2{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one represented by formula 1 as a chemosensitizer that enhances the efficacy of cytotoxic drugs or radiotherapy. This invention provides pharmaceutical combinations of 8-fluoro-2{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one, or a pharmaceutically acceptable salt thereof and at least one additional therapeutic agent, kits containing such combinations and methods of using such combinations to treat subjects suffering from diseases such as cancer.

Methods for radiotherapy to trigger light activation drugs

A method and system for treating a subject with a disorder which provides within the subject at least one photoactivatable drug for treatment of the subject, applies initiation energy from at least one source to generate inside the subject a preferential x-ray flux for generation of Cherenkov radiation (CR) light capable of activating at least one photoactivatable drug, and from the CR light, activating inside the subject the at least one photoactivatable drug to thereby treat the disorder.

Nanoceria for the treatment of oxidative stress

A process for making nanoparticles of biocompatible materials is described, wherein an aqueous reaction mixture comprising cerous ion, citric acid and ethylenediaminetetraacetic acid in a predetermined ratio, an oxidant, and water is provided along with temperature conditions to directly form, without isolation, a stable dispersion of cerium oxide nanoparticles. These biocompatible cerium oxide nanoparticles may be used to prevent and/or treat oxidative stress related diseases, such as stroke, relapse/remitting multiple sclerosis, chronic-progressive multiple sclerosis, amyotrophic lateral sclerosis, and ischemic reperfusion injury.

Nanoparticles of cerium and amino acids

A process for making nanoparticles of biocompatible materials is described, wherein an aqueous reaction mixture comprising cerous ion, an α-amino acid, an oxidant and water is provided along with temperature conditions to effectively form nanoparticles. These biocompatible nanoparticles may be further conjugated to biologically active agents, such as plasmid DNA, siRNA or proteins, such that a cell transfection agent is formed.

Nanoceria for the treatment of oxidative stress

A process for making nanoparticles of biocompatible materials is described, wherein an aqueous reaction mixture comprising cerous ion, citric acid and ethylenediaminetetraacetic acid in a predetermined ratio, an oxidant, and water is provided along with temperature conditions to directly form, without isolation, a stable dispersion of cerium oxide nanoparticles. These biocompatible cerium oxide nanoparticles may be used to prevent and/or treat oxidative stress related diseases, such as stroke, relapse/remitting multiple sclerosis, chronic-progressive multiple sclerosis, amyotrophic lateral sclerosis, and ischemic reperfusion injury.

Nanoceria for neutralizing free radicals

A process for making nanoparticles of biocompatible materials is described, wherein an aqueous reaction mixture comprising cerous ion, citric acid and ethylenediaminetetraacetic acid in a predetermined ratio, an oxidant, and water is provided along with temperature conditions to directly form, without isolation, a stable dispersion of cerium oxide nanoparticles. These biocompatible cerium oxide nanoparticles may be used to prevent and/or treat oxidative stress related diseases, such as stroke, relapse/remitting multiple sclerosis, chronic-progressive multiple sclerosis, amyotrophic lateral sclerosis, and ischemic reperfusion injury.

Biodegradable nanoparticles

The present invention relates to polymeric nanoparticles useful in drug and agent delivery, as well as for imaging, diagnosis and targeting. The polymeric nanoparticles of the present invention comprise polymers and cross-linkers that, when degraded, leave simple nontoxic biocompatible molecules that can be metabolized, excreted, or absorbed by the body. The present invention also relates to processes for producing the polymeric nanoparticles of the present invention, and methods of using them in drug and agent delivery, as well as imaging, diagnosis and targeting.

Iron garnet nanoparticles for cancer radiotherapy and chemotherapy

Iron garnet nanoparticles and or iron garnet particles containing various activatable nuclides, such as holmium-165 ( 165 Ho) and dysprosium-164 ( 164 Dy), are disclosed in this application. The iron garnet (e.g., HoIG and DyIG) nanoparticles and iron garnet particles can prepared using hydroxide co-precipitation methods. In some embodiments, radiosensitizers can be loaded on radioactive magnetic nanoparticles or radioactive iron garnet particles and, optionally, coated with suitable lipid bilayers. Methods of using the disclosed nanoparticles and particles for mediating therapeutic benefit in diseases responsive to radiation therapy are also provided. Another aspect of the invention provides films, electrospun fabrics or bandage coverings for the delivery of radiation to the site of a skin lesion amenable to treatment with radiation (e.g., skin cancers or psoriasis).

一种治疗血磷酸盐过多症的药物及其制备方法

本发明公开了一种治疗血磷酸盐过多症的药物及其制备方法，包括药物有效成份为聚苯乙烯磺酸镧以及药用辅料制成的药剂；本发明的制备方法，取聚苯乙烯磺酸盐用盐酸酸化处理得到聚苯乙烯磺酸后再用水溶性镧盐液浸泡或洗脱，然后用水洗至pH值为中性，再将未交换多余镧离子洗净，取出聚苯乙烯磺酸镧干燥后粉碎成粉状，聚苯乙烯磺酸镧中镧的重量为14-22%，以镧的重量为14-22%的聚苯乙烯磺酸镧粉状为药用有效成份，用常规量的药用辅料按照常规制备方法制成胃肠道用药剂。本发明采用聚苯乙烯磺酸镧为本发明药物的有效成份，以及药用辅料，制作药剂，经过胃肠道给药，使消化道内的磷酸盐形成不溶性结合物，随消化道排出，达到治疗血磷酸盐过多症的目的。

含有选择的碳酸镧水合物的药物组合物

经选择的碳酸镧水合物可以经胃肠道施用，治疗肾衰竭病人的血磷酸盐过多症。

Nanoparticles of cerium and amino acids

A process for making nanoparticles of biocompatible materials is described, wherein an aqueous reaction mixture comprising cerous ion, an a-amino acid, an oxidant, and water is provided along with temperature conditions to effectively form nanoparticles. These biocompatible nanoparticles may be further conjugated to biologically active agents, such as plasmid DNA, siRNA or proteins, such that a cell transfection agent is formed.

Nanoceria for the treatment of oxidative stress

A process for making nanoparticles of biocompatible materials is described, wherein an aqueous reaction mixture comprising cerous ion, citric acid and ethylenediaminetetraacetic acid in a predetermined ratio, an oxidant, and water is provided along with temperature conditions to directly form, without isolation, a stable dispersion of cerium oxide nanoparticles. These biocompatible cerium oxide nanoparticles may be used to prevent and/or treat oxidative stress related diseases, such as stroke, relapse/remitting multiple sclerosis, chronic-progressive multiple sclerosis, amyotrophic lateral sclerosis, and ischemic reperfusion injury.

Multifunctional metal-graphite nanocrystals

Disclosed are nanocrystals comprising metals and metal alloys, which are formed by a process that results in a layer of graphite in direct contact with the metallic core. The nanocrystals may be used in vivo as MRI contrast agents, X-ray contrast agents, near IR (NIR) heating agents, drug delivery, protein separation, catalysis etc. The nanocrystals may be further functionalized with a hydrophilic coating, e.g., phospholipid-polyethylene glycol, which improves in vivo stability. The process comprises chemical vapor deposition of metals adsorbed onto silica as a fine powder, in conjunction with a carbon containing gas, which coats the metal particles. The silica is then etched away. Preferred metals include iron, gold, cobalt, platinum, ruthenium and mixtures thereof, e.g., FeCo and AuFe. The process permits control of the alloy compositions, size, and other characteristics.

Lanthanum Carbonate Hydroxide, Lanthanum Oxycarbonate and Methods of Their Manufacture and Use

The present invention is a method of producing a lanthanum carbonate hydroxide or lanthanum oxycarbonate which has improved properties. The method involves the use of a water soluble lanthanum and a water soluble non-alkali metal carbonate or bicarbonate. The resulting material can be used as a phosphate binder individually or for treating patients with hyperphosphatemia. 1. A lanthanum dioxycarbonate compound which comprises one or more polymorphs of formulae LaOCOand LaCO, and wherein said lanthanum dioxycarbonate compound includes about 0.75% by weight or less of sodium, and has particles having spherical morphology. The present application is a divisional of U.S. patent application Ser. No. 13/106,637, filed May 12, 2011, and U.S. Provisional Patent Application No. 61/333,887 filed May 12, 2010, the disclosures of which are incorporated herein by reference.Pharmaceutical products for use in the treatment of hyperphosphatemia are known in the art. These include those disclosed in U.S. Pat. No. 7,588,782, which describes certain lanthanide containing compounds including lanthanum dioxycarbonate (also referred to herein as LDOC) as well as U.S. Pat. Nos. 5,968,976; 7,381,428; and 7,465,465, describing various lanthanum carbonate hydrates including those of the formula La2(CO3)3.xH2O (also referred to herein as lanthanum tricarbonate). These compounds work by binding phosphate that a subject consumes. One such compound is marketed under the trademark FOSRENOL. Other products for treatment of hyperphosphatemia include RENAGEL, which is a polymeric phosphate binder also known as sevelamer HCl.In particular, U.S. Pat. No. 7,588,782 describes the production of, inter alia, lanthanum dioxycarbonate from a reaction of lanthanum chloride with sodium carbonate to produce what is referred to therein as a lanthanum oxycarbonate (LaO(CO).xHO). This is then heated in a furnace at high temperatures to produce lanthanum dioxycarbonate. See generally the '782 patent, example 5. It ...

Porus silica-containing nanoparticles, production method therefor, and pharmaceutical compostion for radiation treatment

The present invention provides: nanoparticles including a compound that includes porous silica and at least one high-atom selected from the group consisting of gadolinium atoms, iodine atoms, gold atoms, silver atoms, and platinum atoms; and a pharmaceutical composition for radiation treatment, useful for treatment of solid tumors, etc., and including these nanoparticles and a pharmaceutically acceptable carrier.

Cosmetic compositions with near infra-red (NIR) light-emitting material and methods therefor

Cosmetic or dermatological compositions and substrates, containing a NIR light-emitting material, and methods for stimulating healing and/or regenerative properties in the skin, hair and/or scalp are provided.

Diagnosis and treatment of HIV viral infection using magnetic metal transferrin particles

This invention provides methods of treatment and/or diagnosis and/or siting of viruses including the AIDS virus and others as well as the cells which they infect. The method comprises introducing near, into or onto the virus or the cell which the virus infects, or both, minute particles. These particles possess ferromagnetic, paramagnetic or diamagnetic properties. After being localized near, in or on the virus or the viral-infected cell, the particles are inductively heated by application of an alternating electromagnetic field. The inductive heating is continued for a period of time sufficient to bring about a temperature rise to a minimum necessary to kill the virus or cell or to desirably alter the behavior of the virus or infected cell. Prior to, during or after treatment, these particles can be used diagnostically to locate and/or map the virus in the living tissue.

Therapeutic combinations containing inhibitor of poly(adp-ribose)polymerase

FIELD: medicine. ^ SUBSTANCE: invention concerns medical products and concerns the dosed out form for introduction to a mammal, intended for treatment or prevention of a disease state at a mammal mediated by action of PARP where the dosed out form contains chemical combination of formula 1, its pharmaceutically comprehensible salt or a solvate, or their admixtures, in quantity, effective for maintenance of stable size of concentration in plasma, at least, 5.9 ng/ml of the formula chemical combination within, at least, 24 hours after introduction in an organism of a mammal which is the concentration of an inhibitor suppressing (IC89) consumption of cellular NAD+ on 89% and formation of polymer of poly ADP-ribose, and it is corrected taking into account linkage with a protein. The offered dosed out form provides stable size of concentration in plasma of 5.9 ng/ml of AG-014699 within, at least, 24 hours after introduction in an organism of a mammal. ^ EFFECT: maintenance of effective treatment and prevention of a disease state at a mammal mediated by PARP action. ^ 85 cl, 4 dwg, 23 tbl, 12 ex РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) 2 361 592 (13) C2 (51) МПК A61K 31/55 (2006.01) A61P 35/00 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ, ПАТЕНТАМ И ТОВАРНЫМ ЗНАКАМ (12) ОПИСАНИЕ ИЗОБРЕТЕНИЯ К ПАТЕНТУ (21), (22) Заявка: 2007110480/15, 09.09.2005 (24) Дата начала отсчета срока действия патента: 09.09.2005 (43) Дата публикации заявки: 27.09.2008 (45) Опубликовано: 20.07.2009 Бюл. № 20 (85) Дата перевода заявки PCT на национальную фазу: 21.03.2007 2 3 6 1 5 9 2 R U (87) Публикация PCT: WO 2006/033006 (30.03.2006) Адрес для переписки: 129090, Москва, ул. Б.Спасская, 25, стр.3, ООО "Юридическая фирма Городисский и Партнеры", пат.пов. Е.Е.Назиной, рег. № 517 (54) ТЕРАПЕВТИЧЕСКИЕ КОМБИНАЦИИ, СОДЕРЖАЩИЕ ИНГИБИТОР ПОЛИ(АДФ-РИБОЗА)ПОЛИМЕРАЗЫ поли АДФ-рибозы, и скорректирована с (57) Реферат: учетом связывания с белком. Предложенная Изобретение относится к лекарственным ...

生物组织的近红外线损伤的防止剂及使用该防止剂的制品

本发明提供一种生物组织的近红外线损伤的防止剂及使用该防止剂的制品，所述防止剂阻碍近红外线到达皮肤并进一步到达比皮肤组织更深部的组织，防止由近红外线导致的上述组织的损伤，防止由此引起的各种疾病的发病、发展和老化的促进。生物组织的近红外线损伤的防止剂通过含有使近红外线吸收、反射或散射的近红外线透过屏蔽剂，防止暴露于所述近红外线的生物体的皮肤及比皮肤更深部的组织因所述近红外线而受到损伤。生物组织的近红外线损伤的防止制品具有基材的至少一部分涂布、吸附、粘接、贴附有或含有该防止剂的构件，或者是在介质中含有该防止剂的药剂。

氧化铈纳米颗粒在制备治疗和预防肾缺血再灌注损伤的药物中的应用

本发明涉及氧化铈纳米颗粒在制备治疗和/或预防肾缺血再灌注损伤的药物中的应用，属于生物医药技术领域，本发明所制备的氧化铈纳米颗粒降低了HK2细胞(人肾小管上皮细胞)的线粒体膜电位水平和活性氧的产量，提高了HK2细胞在缺氧后复氧的环境中的存活率，并且在动物实验中发现，氧化铈纳米颗粒通过调控炎症反应减轻了缺血再灌注引起的肾脏损伤和后期肾脏纤维化的发生发展。氧化铈纳米颗粒的新应用为临床上治疗和预防肾脏缺血再灌注损伤治疗提供了新思路。

一种二氧化铈纳米粒及其制备方法与应用

本发明公开了一种二氧化铈纳米粒及其制备方法与应用，属于医药技术领域。所述二氧化铈纳米粒包括二氧化铈纳米颗粒，在二氧化铈纳米颗粒表面还修饰有聚合物，所述聚合物选自透明质酸、聚天冬氨酸、葡聚糖或聚谷氨酸。本发明的二氧化铈纳米粒不仅具有良好的的稳定性和优异的生物安全性，还具有抗氧化类酶模拟活性和载药的功能，能够可逆高效消耗体内的各种活性氧（ROS），可单独或负载药物协同治疗动脉粥样硬化（AS），实现药物有效靶向至AS斑块。

Diabetic foot prevention and care composition

FIELD: medicine, pharmaceutics. ^ SUBSTANCE: invention concerns to a diabetic foot prevention and care composition which contains an aqueous solution of polyhexanide hydrochloride with polyethylene glycol 4000, and additionally, mixed nanostructured bentonite powders intercalated by silver ions -(Ag+) and cerium ions (Ce3+) as antimicrobial agents. The composition under the invention contains also a film-forming substance representing an alcoholic solution of polydimethylsiloxane-polyurethane block copolymer with viscosity 10000 to 45000 Pas at 110C and a local anaesthetic substance. ^ EFFECT: composition provides faster skin regeneration and healing. ^ 7 cl, 3 ex РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) 2 427 379 (13) C1 (51) МПК ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ, ПАТЕНТАМ И ТОВАРНЫМ ЗНАКАМ (12) ОПИСАНИЕ A61K B82B A61K A61K A61K A61P B82Y 33/38 (2006.01) 1/00 (2006.01) 31/155 (2006.01) 47/30 (2006.01) 9/06 (2006.01) 17/02 (2006.01) 5/00 (2011.01) ИЗОБРЕТЕНИЯ К ПАТЕНТУ (21)(22) Заявка: 2010138449/15, 20.09.2010 (24) Дата начала отсчета срока действия патента: 20.09.2010 (45) Опубликовано: 27.08.2011 Бюл. № 24 агентов. Состав по изобретению включает также пленкообразующее вещество, представляющее собой спиртовой раствор блок-сополимера полидиметилсилоксана и полиуретана с вязкостью при 110°С от 10000 до 45000 Па·с и местноанестезирующее вещество. Заявленный состав обеспечивает ускорение регенерации и заживления кожных покровов. 6 з.п. ф-лы. (57) Реферат: Изобретение относится составу для профилактики и ухода за диабетической стопой, который содержит водный раствор полигексанида гидрохлорида с полиэтиленгликолем 4000, и дополнительно смесь наноструктурных порошков бентонита, интеркалированных ионами серебра (Ag +) и ионами церия (Се 3+) в качестве антимикробных R U 2 4 2 7 3 7 9 (54) СОСТАВ ДЛЯ ПРОФИЛАКТИКИ И УХОДА ЗА ДИАБЕТИЧЕСКОЙ СТОПОЙ Ñòð.: 1 ru C 1 C 1 Адрес для переписки: 124482, Москва, Зеленоград, Савелкинский пр-д, 4, оф.1314, ЗАО "Институт ...

具有新结构的化合物、包含其的抗炎剂及环氧化酶-2抑制剂

在本发明的化合物、包括其的抗炎剂、环氧化酶‑2抑制剂、脑疾病治疗剂、以及MRI造影剂中，本发明的化合物具有由本发明的化学式1表示的结构。

Nanoceria for the treatment of oxidative stress

생체적합성 물질의 나노입자를 제조하는 방법이 기술되어 있으며, 여기에서 제1세륨 이온, 소정 비율의 시트르산 및 에틸렌디아민테트라아세트산, 산화제 및 물을 포함하는 수성 반응 혼합물이 분리 없이 안정한 세륨 옥사이드 나노입자의 안정한 분산액을 직접적으로 형성시키는 온도 조건과 함께 제공된다. 이러한 생체적합한 세륨 옥사이드 나노입자는 발작, 재발/완화형 다발성 경화증, 만성-진행형 다발성 경화증, 근위축성 측삭 경화증 또는 허혈성 재관류 손상과 같은 산화 스트레스 관련 질환의 예방 및/또는 치료에 사용될 수 있다. A method of making nanoparticles of a biocompatible material is disclosed wherein an aqueous reaction mixture comprising a first cerium ion, a predetermined proportion of citric acid and ethylenediaminetetraacetic acid, an oxidizing agent and water is mixed with a cerium oxide nanoparticle And is provided with temperature conditions that directly form a stable dispersion. Such biocompatible cerium oxide nanoparticles can be used for the prevention and / or treatment of oxidative stress related diseases such as seizures, recurrent / ameliorated multiple sclerosis, chronic-progressive multiple sclerosis, amyotrophic lateral sclerosis or ischemic reperfusion injury.

含有镧化合物的胶囊和粉末制剂

本发明包括含有外壳、碳酸镧或碳酸镧水合物和润滑剂(例如滑石粉)的口服药物胶囊，其中外壳包封碳酸镧或其水合物和润滑剂。胶囊外壳包含例如明胶。本发明还包括含有碳酸镧或碳酸镧水合物和可药用赋形剂的口服药物粉末。可以施用本发明的口服药物胶囊和粉末以治疗处于高磷酸盐血症风险之中或患有高磷酸盐血症、处于慢性肾病(CKD)风险之中或患有慢性肾病(CKD)、处于与CKD相关的软组织钙化风险之中或患有与CKD相关的软组织钙化，或者处于继发性甲状旁腺功能亢进症风险之中或患有继发性甲状旁腺功能亢进症的患者。

具有发射近红外(nir)光的材料的化妆品组合物及其方法

提供了含有发射NIR光的材料的化妆品或皮肤病学组合物和基材，和用于刺激皮肤、毛发和/或头皮的愈合和/或再生特性的方法。

Composition based on cerium dioxide nanoparticles and brown algae polysaccharides for treating wounds

FIELD: medicine. SUBSTANCE: group of inventions refers to medicine and aims at treating wounds, burns, inflammatory conditions of skin and mucous membranes. External composition for treating wounds and destructive lesions of mammal mucosa and skin contains an effective amount of cerium oxide nanoparticles, a pharmaceutically acceptable carrier, a target additive and water. Said carrier contains water-soluble cellulose derivatives and water-soluble polysaccharides of brown algae - pectin, fucoidin and alginate. Carrier is made in soft nontoxic, biocompatible and moisture and gas permeable form. Target additive is selected from: immunomodulators, antibacterial preparations, stimulators of reparative processes, analgesics, anaesthetics, anti-inflammatory agents, antioxidants, vitamins, polysaccharides or their mixtures. Components are used in claimed amounts. Another embodiment is use of said composition for preparing a medicinal agent for applying on skin surface and wound in treating and recovering skin and soft tissues. Also, container is provided for arrangement and further external application of said composition. EFFECT: using the group of inventions enables providing more effective treatment of wounds, burns, inflammatory conditions of skin and mucous membranes ensured by synergetic action of the components of the composition, as well as providing simplicity and ease of use during treatment. 9 cl, 4 dwg, 1 tbl, 4 ex РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (13) 2 699 362 C2 (51) МПК A61K 33/244 (2019.01) A61K 36/00 (2006.01) A61K 47/36 (2006.01) A61K 47/38 (2006.01) B82B 1/00 (2006.01) A61P 17/02 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ОПИСАНИЕ ИЗОБРЕТЕНИЯ К ПАТЕНТУ (52) СПК A61K 33/244 (2019.05); A61K 36/00 (2019.05); A61K 47/36 (2019.05); A61K 47/38 (2019.05); B82B 1/00 (2019.05); A61K 2121/00 (2019.05); A61P 17/02 (2019.05) (21)(22) Заявка: 2018101481, 16.01.2018 16.01.2018 Дата регистрации: 05.09.2019 (43) Дата публикации заявки: 16.07. ...

COMPOSITION ON THE BASIS OF CERIUM DIOXIDE NANOPARTICLES AND POLYSACCHARIDES OF BROWN ALGAE FOR TREATMENT OF THE RAS

РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (13) 2018 101 481 A (51) МПК A61K 36/00 (2006.01) B82B 1/00 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ЗАЯВКА НА ИЗОБРЕТЕНИЕ (21)(22) Заявка: 2018101481, 16.01.2018 (71) Заявитель(и): ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НОВАСКИН" (ООО "Новаскин") (RU) Приоритет(ы): (22) Дата подачи заявки: 16.01.2018 (43) Дата публикации заявки: 16.07.2019 Бюл. № 20 A 2 0 1 8 1 0 1 4 8 1 R U оксид церия 0,00000172-0,000172 водорастворимые производные целлюлозы 1,0-15,0 водорастворимый полисахарид пектин 0,01-1,5 водорастворимый полисахарид фукоидин 0,01-1,5 водорастворимый полисахарид альгинат 0,01-1,5 целевая добавка 0,01-1,0 вода остальное 2. Композиция по п. 1, отличающаяся тем, что оксид церия имеет форму стабильного водного золя стабилизированного стабилизатором, который выбран из группы, состоящей из лецитина, декстрана, цитрата аммония, полиакриловой кислоты. 3. Композиция по п. 1, отличающаяся тем, что оксид церия имеет форму стабильного водного золя стабилизированного цитратом аммония. 4. Композиция по п. 1, отличающаяся тем, что водорастворимые производные целлюлозы выбирают из группы, состоящей из карбоксиметилцеллюлозы, целлосайза или их комбинации. 5. Композиция по п. 1, отличающаяся тем, что целевую добавку выбирают из ряда: Стр.: 1 A (57) Формула изобретения 1. Композиция наружного применения для лечения ран и деструктивных поражений слизистой и кожи млекопитающих, содержащая эффективное количество наночастиц оксида церия, фармацевтически приемлемый носитель, отличающаяся тем, что носитель выполнен в мягкой нетоксичной, биосовместимой и проницаемой для влаги и газов форме, при этом носитель включает водорастворимые производные целлюлозы и водорастворимые полисахариды бурых водорослей, входящие в группу, состоящую из: пектина, фукоидина, альгината или их смеси при следующем соотношении компонентов, мас. %: 2 0 1 8 1 0 1 4 8 1 (54) КОМПОЗИЦИЯ НА ОСНОВЕ НАНОЧАСТИЦ ДИОКСИДА ЦЕРИЯ И ПОЛИСАХАРИДОВ БУРЫХ ...

Lanthanum carbonate hydroxide, lanthanum oxycarbonate and methods for thereof obtaining and application

Изобретение относится к способам получения соединений карбоната лантана и их применению, а именно к способам получения гидроксида карбоната лантана и диоксикарбоната лантана и фармацевтической композиции, содержащей диоксикарбонат лантана. Способ получения соединения карбоната лантана включает осуществление реакции растворимой соли хлорида лантана с карбонатом аммония в растворителе при температуре реакции от примерно 75 градусов Цельсия до примерно 90 градусов Цельсия, при рН от примерно 6,0 до 7,5, и осаждение продукта реакции, при этом продукт реакции представляет собой гидроксид карбонат лантана, содержащий примерно 0,5 масс. % или меньше натрия. При дополнительном обжиге продукта реакции при температуре от примерно 400 до примерно 700 градусов Цельсия в течение двух часов получают диоксикарбонат лантана, содержащий одну или более полиморфных форм формул La 2 O 2 CO 3 и La 2 CO 5 и содержащий примерно 0,75 масс. % или меньше натрия. Изобретение обеспечивает получение соединений карбоната лантана, обладающих улучшенными свойствами. 4 н. и 17 з.п. ф-лы, 23 ил., 20 табл., 8 пр. РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (13) 2 570 007 C2 (51) МПК C01F 17/00 (2006.01) A61K 33/24 (2006.01) A61P 7/08 (2006.01) A61P 13/12 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ОПИСАНИЕ (21)(22) Заявка: ИЗОБРЕТЕНИЯ К ПАТЕНТУ 2012146818/05, 12.05.2011 (24) Дата начала отсчета срока действия патента: 12.05.2011 Приоритет(ы): (30) Конвенционный приоритет: (43) Дата публикации заявки: 20.06.2014 Бюл. № 17 (45) Опубликовано: 10.12.2015 Бюл. № 34 (85) Дата начала рассмотрения заявки PCT на национальной фазе: 12.12.2012 (86) Заявка PCT: 2 5 7 0 0 0 7 (56) Список документов, цитированных в отчете о поиске: WO 2006/044657 A2, 27.04.2006. US 2006/0153932 A1, 13.07.2006. US 7588782 B2, 15.09.2009. RU 2296584 С2, 10.04.2007. (73) Патентообладатель(и): СПЕКТРУМ ФАРМАСЬЮТИКАЛЗ, ИНК. (US) R U 12.05.2010 US 61/333,887 (72) Автор(ы): ДИКСИТ Милинд (US), ГОР Ашок Йешвант (US), ...

CICATRISANTE COMPOSITION

The effects of antibacterial agents on the behaviour of mouse fibroblasts in vitro

Radiopaque embolic particles

本发明公开了不透射线的颗粒状物质，其包含SiO 2 、TiO 2 、La 2 O 3 、Na 2 O和MgO中的一种或多种并且可用于栓塞术中，其任选地包括体内释放的治疗组分。

Radiopaque embolic particles

A radiopaque particulate material one or more of SiO

radiopaque embolic particles

本发明公开了不透射线的颗粒状物质，其包含SiO 2 、TiO 2 、La 2 O 3 、Na 2 O和MgO中的一种或多种并且可用于栓塞术中，其任选地包括体内释放的治疗组分。

Assay for lanthanum hydroxycarbonate

An assay for analytically determining the amount of an impurity in a solid sample is provided. This X-ray diffraction method preferably uses the Rietveld refinement.

Method for use of lanthanum carbonate pharmaceutical compositions

A method for treating hyperphosphatemia using lanthanum carbonate, including analytically determining the amount of an impurity in the lanthanum carbonate sample is provided. This X-ray diffraction method preferably uses the Rietveld refinement.

Pharmaceutical comprising an agent that blocks the cell cycle and an antibody

Pharmaceutical combinations comprising an agent that arrests target cells in the G 2 and/or M phase of the cell cycle and another therapeutic agent that targets an internalising cell surface structure such as an antigen. Use in the manufacture of a medicament and in methods of medical treatment, particularly in the treatment of diseases of cell cycle regulation such as cancer are disclosed.

Method of treatment of neuroendocrine tumors

The present invention relates to methods of treating cancers that overexpress somatostatin receptors, e.g. neuroendocrine tumors (NET). In particular, the invention provides novel therapies based on the combination of a peptide receptor radionuclide therapeutic (PRRT) agent and immuno-oncology (I-O) therapeutic agents, wherein said I-O therapeutic agents are selected from the group consisting of LAG-3 inhibitors, TIM-3 inhibitors, GITR angonists, TGF-β inhibitors, IL15/IL-15RA complex, and selected PD-1 inhibitors.

Capsule preparation and powder preparation containing lanthanum compound

Functionalized colloidal metal compositions and methods

本发明包括用于制备官能化/反应性胶态金属组合物的方法和组合物及其用途。本发明包括用于试剂传递系统的组合物和方法，包括治疗化合物、药剂、药物、检测剂、核酸序列和生物因子。一般而言，这些媒介物组合物包括官能化/反应性胶态金属和试剂。本发明还包括治疗癌症的方法和组合物。

Metal-containing formulations and methods of use

Metal-containing materials, as well as their preparation, formulations, and use are disclosed.

Composition for transdermal delivery of nanoparticles

FIELD: medicine.SUBSTANCE: invention relates to the field of medicine, in particular, to the field of development of therapeutic and cosmetic compositions and application thereof for delivery of inorganic particles, specifically cerium dioxide nanoparticles, through the skin. A composition for transdermal delivery of nanoparticles is proposed, containing dimethyl sulphoxide as a penetrator and nanocrystalline cerium dioxide as nanoparticles, bound to a stabiliser constituting a polysaccharide, with the following ratio of components, % wt.: cerium dioxide nanoparticles - 1.7; stabiliser - 8.3; dimethyl sulphoxide - 90. Low-molecular polyglucans can be used as a stabiliser.EFFECT: ensures maximum penetration of cerium dioxide nanoparticles through the skin barrier to a depth of up to 20 mcm.2 cl, 4 dwg, 4 ex РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (13) 2 753 699 C1 (51) МПК A61K 33/244 (2019.01) A61K 47/20 (2006.01) A61K 47/36 (2006.01) B82Y 5/00 (2011.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ОПИСАНИЕ ИЗОБРЕТЕНИЯ К ПАТЕНТУ (52) СПК A61K 33/244 (2021.05); A61K 47/20 (2021.05); A61K 47/36 (2021.05); B82Y 5/00 (2021.05) (21)(22) Заявка: 2021101640, 26.01.2021 (24) Дата начала отсчета срока действия патента: Дата регистрации: 19.08.2021 (45) Опубликовано: 19.08.2021 Бюл. № 23 Адрес для переписки: 142290, Московская обл., г. Пущино, мкр. АБ, 27, кв. 31, Попов А.Л. 2 7 5 3 6 9 9 C 1 (56) Список документов, цитированных в отчете о поиске: RU 2500381 C1, 10.12.2013. RU 2484832 C1, 20.06.2013. RU 2615688 C1, 06.04.2017. US 10201571 B2, 12.02.2019. ЩЕРБАКОВ А.Б. и др. Наноматериалы на основе диоксида церия: свойства и перспективы использования в биологии и медицине. Биотехнология, 2011, т.4, N1, с.9-28. ЩЕРБАКОВ А.Б. Синтез и антиоксидантная активность биосовместимых водных золей (см. прод.) (54) КОМПОЗИЦИЯ ДЛЯ ТРАНСДЕРМАЛЬНОЙ ДОСТАВКИ НАНОЧАСТИЦ (57) Реферат: Изобретение относится к области медицины, стабилизатором, представляющим собой в частности к области ...

Preparation method of temperature-sensitive hydrogel and temperature-sensitive hydrogel

本申请提供了一种温敏水凝胶的制备方法，通过铈掺杂生物活性玻璃，以温敏高分子材料为载体，负载所述铈掺杂生物活性玻璃，得到所述温敏水凝胶，上述温敏水凝胶接触体液后，通过降解释放铈离子和硅、钙等生物活性离子，在清除创面过量活性氧的同时，促进创面修复，有助于糖尿病溃疡等慢性创面的治疗。另外，本申请还提供了一种温敏水凝胶。

METHOD OF PRODUCING CARRIER-FREE HIGH-PURITY 177Lu COMPOUNDS AND CARRIER-FREE 177Lu COMPOUNDS

FIELD: chemistry. SUBSTANCE: invention relates to a method of producing carrier-free high-purity 177 Lu compounds for medical purposes and/or diagnostic purposes. A method of producing 77 Lu compounds from l76 Yb compounds, irradiated with thermal neutrons, includes loading into a first column, filled with a cation-exchange material, starting materials dissolved in mineral acid and containing l77 Lu and 176 Yb in an approximate weigh ratio of 1:10 2 to 1:10 10 ; replacing protons of the cation-exchange material with ammonium ions using NH 4 Cl solution, washing the cation-exchange material with water; connecting the outlet opening of the first column and the inlet opening of a second column; feeding water and a chelating agent into the inlet opening of the first column in order to elute 177 Lu compounds from the first and second columns; determining the level of radioactive radiation at the outlet of the second column to confirm elution of the 177 Lu compounds; collecting the first 177 Lu eluate from the outlet opening of the second column into a vessel; protonating the chelating agent; loading the final column by continuously feeding the obtained l77 Lu eluate into the inlet opening of the final column; washing off the chelating agent with diluted mineral acid; removing traces of ions of other metals from the l77 Lu solution by washing the cation-exchange material of the final column with mineral acid in different concentrations and eluting 177 Lu ions from the final column with highly concentrated mineral acid. EFFECT: invention enables to obtain milligram amounts of carrier-free high-purity 177 Lu compounds. 16 cl, 4 dwg, 1 ex РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (51) МПК G21G 4/04 G21G 4/08 C01F 17/00 B01J 45/00 (13) 2 573 475 C2 (2006.01) (2006.01) (2006.01) (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ОПИСАНИЕ (21)(22) Заявка: ИЗОБРЕТЕНИЯ К ПАТЕНТУ 2013155710/05, 12.04.2012 (24) Дата начала отсчета срока действия патента: 12.04.2012 ...

Oral composition for phosphorous compounds absorption

FIELD: medicine, pharmaceutics. ^ SUBSTANCE: present invention refers to an oral pharmaceutical composition taken between meals for phosphorous compounds absorption from the intestinal liquids, especially from saliva. The composition contains a phosphorus binding agent, and a pharmaceutically acceptable carrier and/or an excipient. The composition is kept in a mouth to exhaust the phosphorus binding agent. The phosphorus binding agent represents a phosphate binding agent polymer, a pharmaceutically acceptable lanthanum salt, a pharmaceutically acceptable magnesium salt, a pharmaceutically acceptable calcium salt, a pharmaceutically acceptable anion-exchange resin, a pharmaceutically acceptable phosphate binding polysaccharide. Preferentially, the agent represents phosphate binding chitosan. The composition is used for treating hyperphosphatemia. ^ EFFECT: invention provides effective treatment of high blood serum phosphorus concentration and reduces risk of cardiovascular complications in patients. ^ 19 cl, 2 tbl, 2 ex РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) 2 392 926 (13) C2 (51) МПК A61K A61K A61K A61K A61K A61P 9/22 (2006.01) 31/722 (2006.01) 31/785 (2006.01) 33/08 (2006.01) 33/10 (2006.01) 7/00 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ, ПАТЕНТАМ И ТОВАРНЫМ ЗНАКАМ (12) ОПИСАНИЕ ИЗОБРЕТЕНИЯ К ПАТЕНТУ (21), (22) Заявка: 2007125702/15, 29.11.2005 (24) Дата начала отсчета срока действия патента: 29.11.2005 (73) Патентообладатель(и): СМ эрд Д Фарма Лимитед (GB) R U (30) Конвенционный приоритет: 07.12.2004 IT ME2004A000015 (72) Автор(ы): САВИКА Винченцо (IT) (43) Дата публикации заявки: 20.01.2009 C 2 (56) Список документов, цитированных в отчете о поиске: US 5496545 A, 05.03.1996. JP 05-213762 A, 24.08.1993. US 4163777 A, 07.08.1979. US 2003/138518 A1, 24.07.2003. WO 02/051259 A, 04.07.2002. JP 62-132830 A, 16.06.1987. US 4814176 A, 21.03.1989. EP 1046410 A, 25.10.2000. US 5968976 A, 19.10.1999. EP 0793960 A, 10.09.1997. EP 0426098 A, 08.05.1991. C 2 2 ...

Composition for healing

Изобретение относится к фармацевтической промышленности, в частности к композиции для ранозаживляющего наполнения кожного повреждения, при котором имеет место потеря кожного материала. Композиция для ранозаживляющего наполнения кожного повреждения, при котором имеет место потеря кожного материала, включает мед, глину и масло, обогащенное линолевой и линоленовой кислотами. Способ получения композиции. Косметическая композиция. Перевязочный материал. Лекарственный препарат (варианты). Вышеописанная композиция эффективна для ранозаживляющего наполнения кожного повреждения, при котором имеет место потеря кожного материала. 7 н. и 10 з.п. ф-лы, 1 ил., 1 табл. РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) 2 410 119 (13) C2 (51) МПК A61K 45/06 (2006.01) A61P 17/02 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ, ПАТЕНТАМ И ТОВАРНЫМ ЗНАКАМ (12) ОПИСАНИЕ ИЗОБРЕТЕНИЯ К ПАТЕНТУ (21)(22) Заявка: 2008143742/15, 10.04.2007 (24) Дата начала отсчета срока действия патента: 10.04.2007 (73) Патентообладатель(и): ЛАБОРАТУАР АГЭТТАН (FR), ФРЕГОНЕС АЛЕКСАНДРА (FR) R U Приоритет(ы): (30) Конвенционный приоритет: 10.04.2006 FR 06/03188 (72) Автор(ы): ФРЕГОНЕС Александра (FR) (43) Дата публикации заявки: 20.05.2010 Бюл. № 14 2 4 1 0 1 1 9 (45) Опубликовано: 27.01.2011 Бюл. № 3 2 4 1 0 1 1 9 (85) Дата начала рассмотрения заявки PCT на национальной фазе: 10.11.2008 C 2 C 2 (56) Список документов, цитированных в отчете о поиске: RO 119065 В1, 30.03.2004. КАЛАНОВ Р.Г. и др. Комплексное лечение гнойновоспалительных заболеваний с применением масла калины. Здравоохр. Башкортостана, 1997, №3, с.34-38, реферат. GB 2382527 А, 04.06.2003. WO 0141776 A2, 14.06.2001. (86) Заявка PCT: FR 2007/000602 (10.04.2007) (87) Публикация заявки РСТ: WO 2007/116147 (18.10.2007) Адрес для переписки: 191002, Санкт-Петербург, а/я 5, ООО "Ляпунов и партнеры", пат.пов. Ю.В.Кузнецовой R U (54) КОМПОЗИЦИЯ ДЛЯ ЗАЖИВЛЕНИЯ (57) Реферат: Изобретение относится к фармацевтической промышленности, в частности к композиции для ...

Composition for treating wounds and burns (embodiments)

FIELD: medicine. SUBSTANCE: invention refers to medicine, namely to medicinal compositions. Proposed composition contains water-soluble cellulose derivatives and water-soluble polysaccharides of brown algae - pectin and alginate, water, wherein the disclosed composition further contains chitosan, agar-agar, fibroblast growth factor (FGF), wt. %: pectin 0.05–0.1; sodium alginate 0.01–0.05; chitosan 0.005–0.01; agar-agar 0.05–0.1; water-soluble cellulose derivatives 1–2; fibroblast growth factor (FGF) 0.00005–0.0002; water is balance. Also disclosed is another embodiment of the composition for treating wounds and burns, which contains said components in the same proportions, as well as cerium oxide in form of a colloidal sol of nanoparticles, wt.%: 0.000002-0.0002. EFFECT: invention can be used for treating wounds and burns. 2 cl, 1 tbl, 4 ex РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (13) 2 734 819 C1 (51) МПК A61K 33/244 (2019.01) A61K 36/00 (2006.01) A61K 47/36 (2006.01) A61K 47/38 (2006.01) A61K 38/18 (2006.01) A61P 17/02 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ОПИСАНИЕ ИЗОБРЕТЕНИЯ К ПАТЕНТУ (52) СПК A61K 33/244 (2020.05); A61K 36/00 (2020.05); A61K 47/36 (2020.05); A61K 47/38 (2020.05); A61K 38/18 (2020.05); A61P 17/02 (2020.05) (21)(22) Заявка: 2019141030, 12.12.2019 12.12.2019 Дата регистрации: Приоритет(ы): (22) Дата подачи заявки: 12.12.2019 (45) Опубликовано: 23.10.2020 Бюл. № 30 2 7 3 4 8 1 9 R U (54) Композиция для лечения ран и ожогов (варианты) (57) Реферат: Изобретение относится к области медицины, а именно к лекарственным композициям, и может быть использовано при лечении ран и ожогов. Предлагаемая композиция содержит водорастворимые производные целлюлозы и водорастворимые полисахариды бурых водорослей - пектин и альгинат, воду, причем предлагаемая композиция дополнительно содержит хитозан, агар-агар, фактор роста фибробластов (FGF), мас. %: пектин 0,05-0,1; Стр.: 1 альгинат натрия 0,01-0,05; хитозан 0,005-0,01; агар-агар 0,05-0,1; ...

Ceria nanocomposite, pharmaceutical formulation comprising the same, and process for preparing the sames

본 발명은 세리아 나노복합체, 이를 포함하는 약학 조성물 및 이의 제조 방법에 관한 것이다. 보다 상세하게는, 본 발명은 계면활성제로 둘러싸인 세리아 나노입자를 폴리에틸렌 글리콜-인지질로 캡핑(capping)한 구조를 갖는 나노복합체와, 이를 포함하는 허혈성 뇌졸중 치료 또는 예방용 약학 조성물 및 이들의 제조 방법에 대한 것이다.

Metal containing composite materials

본 발명은 금속 함유 물질 또는 복합 물질을 제조하는 방법에 관한 것이며, 상기 방법은 중합성 쉘 내에 적어도 하나의 금속계 화합물을 캡슐화시켜 이에 의해 중합체-캡슐화 금속계 화합물을 제조하는 단계; 및/또는 중합성 입자를 적어도 하나의 금속계 화합물로 코팅하는 단계; 적절한 가수분해성 또는 비가수분해성 졸/겔 형성 성분으로부터 졸을 형성하는 단계; 중합체-캡슐화 금속계 화합물 및/또는 코팅된 중합성 입자를 졸과 혼합하고, 이에 의해 이의 혼합물을 제조하는 단계; 혼합물을 고형 금속 함유 물질로 전환하는 단계를 포함한다. 금속 함유 물질, 중합체 캡슐화 금속계 화합물, 졸, 복합 물질

Antiallergic combinations of calcium and lanthanum salts

FIELD: medicine, pharmaceutics. SUBSTANCE: group of inventions refers to medicine, namely to clinical allergology, and may be used for extracorporeal allergen denaturation. That is ensured by treating a surface of objects with an allergen-denaturing composition. The composition contains calcium chloride or calcium acetate and lanthanum chloride or lanthanum nitrate in certain proportions. EFFECT: combinations of the above metal salts selected in certain proportions provide the effective allergen denaturation ex vivo by a synergistic denaturation action of the given ingredients. 9 cl, 4 tbl РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (13) 2 513 948 C2 (51) МПК A61K 33/00 (2006.01) A61K 33/06 (2006.01) A61P 11/06 (2006.01) A61L 2/16 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ОПИСАНИЕ (21)(22) Заявка: ИЗОБРЕТЕНИЯ К ПАТЕНТУ 2011108553/14, 07.08.2009 (24) Дата начала отсчета срока действия патента: 07.08.2009 (72) Автор(ы): БИЛЕМАНС Дэни Леопольд Жозефин (BE) (73) Патентообладатель(и): ЯНССЕН ФАРМАЦЕВТИКА НВ (BE) Приоритет(ы): (30) Конвенционный приоритет: (43) Дата публикации заявки: 20.09.2012 Бюл. № 26 R U 08.08.2008 EP 08162069.2 (45) Опубликовано: 20.04.2014 Бюл. № 11 (85) Дата начала рассмотрения заявки PCT на национальной фазе: 09.03.2011 C 2 C 2 C2, 20.11.2006. EP 1131999 A2, 12.09.2001. DD 280692 A1, 18.07.1990. MARTYNY J.W. et all, Aerosolized sodium hypochlorite inhibits viability and allergenicity of mold on building materials, J Allergy Clin Immunol. 2005 Sep; 116(3):630-5, найдено из интернет: (см. прод.) (86) Заявка PCT: EP 2009/060260 (07.08.2009) 2 5 1 3 9 4 8 (87) Публикация заявки PCT: R U 2 5 1 3 9 4 8 (56) Список документов, цитированных в отчете о поиске: EP 1133918 A1, 19.09.2001. RU 2287325 WO 2010/015697 (11.02.2010) Адрес для переписки: 129090, Москва, ул. Б. Спасская, 25, строение 3, ООО "Юридическая фирма Городисский и Партнеры" (54) АНТИАЛЛЕРГЕННЫЕ КОМБИНАЦИИ СОЛЕЙ КАЛЬЦИЯ И ЛАНТАНА (57) Реферат: Группа изобретений относится к ...

Metal oxide complexes and infusion of complexes into polymer compounds

Described is an initial liquid composition with at least antimicrobial, antibacterial, and/or anti-viral properties comprising chelated metal oxide particles suspended in a polyol, such that metal oxide particles are homogeneously dispersed in the primarily liquid based polyol carrier and such that the chelated metal oxide particles form a stable complex suspension that can eventually become an alkaline based aqueous silver oxide dispersion. The suspension can be optionally further complexed with a combination of chitosan where the resulting metal oxide complex is provided in a concentration of between 0.1 and 25 weight percent. The liquid composition (with or without chitosan) can be subsequently added to essentially any polymer or polymer compound/system where the polymer degrades or melts at a temperature lower than the polyol carrier degradation or boiling temperature. The metal oxide complex may also impart beneficial semi-conductive or conductive as well as permeability and flammability property changes to the polymer (host) system. This technique allows for providing chelated metal oxide complexes to essentially any polymeric host without substantially altering the necessary physio-chemical properties of the original polymeric system. Use of the polyol chelated metal oxide complex additive carrier infused into a polymeric, food and/ or beverage host is also included.

Nanoparticle compositions and methods for treating or preventing tissue infections and diseases

Stabilized multi-component antimicrobial compositions for treating tissue diseases, infections or conditions include a first and second set of differently sized and/or differently shaped metal nanoparticles, and a stabilizing agent. Compositions and treatment methods may be used for treating tissue diseases, infections or conditions caused by microbial infections, such as bacteria, viral, and/or fungal infections, or for preventing the infection of a wound, such as a cut, abrasion, ulcer, lesion, sore, and the like. The compositions and treatment methods disclosed herein may also be used as a prophylactic, and in some embodiments may be applied to otherwise healthy tissue in order to prevent or reduce the occurrence of a tissue disease, infection or condition.

Nanoparticle compositions and methods for treating onychomychosis

A nanoparticle composition for treating onychomycosis includes spherical-shaped nanoparticles having a particle size and a particle size distribution and coral-shaped nanoparticles having a particle size and a particle size distribution mixed within a penetrating solvent configured to deliver the nanoparticles to target area of a nail and/or surrounding tissue. The nanoparticle composition can be mixed with a carrier to provide or augment application of the nanoparticle composition to a target area. The penetrating solvent can deliver the nanoparticles to an infected area within the nail and/or at the bed of the nail so as to kill or deactivate the fungal microbes causing the onychomycosis.